The DOI matches its Crossref record.
A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers
Open accessAbstract
BACKGROUND: Tamoxifen reduces the risk of breast cancer in women at high risk for the disease but increases the risk for endometrial tumors and venous thromboembolisms, possibly in a dose-dependent fashion. We compared the effects of tamoxifen at 1 mg/day and 5 mg/day with those of the standard dose of 20 mg/day on breast cancer proliferation using a surrogate endpoint marker (Ki-67 expression) and blood biomarkers associated with breast cancer, cardiovascular disease, and bone fracture risk. METHODS: We randomly assigned 120 women with estrogen receptor (ER)-positive breast cancer to tamoxifen at 1, 5, or 20 mg/day for 4 weeks. Expression of the tumor proliferation marker Ki-67 and of biomarkers of breast cancer (insulin-like growth factor-I, sex hormone-binding globulin), cardiovascular disease (cholesterol, triglycerides, ultrasensitive C-reactive protein, fibrinogen, antithrombin-III), and bone fracture (type I collagen C-telopeptide) risk were determined before (baseline) and after treatment. All levels were compared with those in two nonrandomized control groups (34 women with ER-negative breast cancer and 29 additional women with ER-positive breast cancer). Data were analyzed by analysis of covariance. All statistical tests were two-sided. RESULTS: Expression of Ki-67 decreased in all three tamoxifen groups, with no difference in the magnitude of reduction among groups (P =.81). Relative to baseline, Ki-67 expression decreased by a median of 15.0% (95% confidence interval = 0.0% to 24.1%) among the tamoxifen groups but increased by 12.8% (95% confidence interval = 0.0% to 19.6%) among the nonrandomized control groups. Several blood biomarkers showed dose-response relationships with tamoxifen, including decreased insulin-like growth factor-I, increased sex hormone-binding globulin, and decreased low-density lipoprotein-cholesterol, ultrasensitive C-reactive protein, fibrinogen, and antithrombin-III levels. CONCLUSIONS: The effects on Ki-67 expression of lower doses of tamoxifen were comparable to those achieved with the standard dose, although the effects on blood biomarkers were variable. The effects of lower doses of tamoxifen should be assessed further in randomized trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. N. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 507
Wildiers, H., Kunkler, I., Biganzoli, L., Fracheboud, J., Vlastos, G., Bernard-Marty, C., Hurria, A., Extermann, M., Girre, V., Brain, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70378-9 · Cited by 338
Metadata
- Authors
- Decensi, A., Robertson, C., Viale, G., Pigatto, F., Johansson, H., Kisanga, E. R., Veronesi, P., Torrisi, R., Cazzaniga, M., Mora, S., Sandri, M. T., Pelosi, G., Luini, A., Goldhirsch, A., Lien, E. A., & Veronesi, U.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-06-04
- Volume
- 95
- Issue
- 11
- Pages
- 779-790
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2111417767
- Cited by
- 221
- References
- 0
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers. https://app.cochat.ai/papers/10.1093/jnci/95.11.779
- The paper
- Decensi, A., Robertson, C., Viale, G., Pigatto, F., Johansson, H., Kisanga, E. R., Veronesi, P., Torrisi, R., Cazzaniga, M., Mora, S., Sandri, M. T., Pelosi, G., Luini, A., Goldhirsch, A., Lien, E. A., & Veronesi, U. (2003). A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/95.11.779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.